Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer

Trial Profile

Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs SPARC-1613 (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Pharmacokinetics
  • Sponsors Sun Pharma Advanced Research Company
  • Most Recent Events

    • 06 Jun 2018 Planned End Date changed from 30 Jun 2018 to 28 Feb 2019.
    • 06 Jun 2018 Planned primary completion date changed from 30 Jun 2018 to 28 Feb 2019.
    • 02 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top